Hosted on MSN11h
GSK lowered to hold by Jefferies, valuation disconnect cited
Jefferies said it still regards GSK’s fundamental value as “compelling,” adding that its 2027+ estimates for sales and ...
Business Insider23h
GSK downgraded to Hold from Buy at Jefferies
While GSK’s fundamental value remains compelling, overhangs for the company’s Arexvy and Shingrix vaccines, “more subdued” 2025 growth, and few near-term catalysts to “rebuild belief” suggests the ...